How Cefuroxime Axetil Works — Second-Generation Cephalosporin for Pediatric Infections
Cefuroxime axetil is an oral prodrug that converts to active cefuroxime after intestinal absorption. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) — producing bactericidal activity against both gram-positive and gram-negative pathogens including Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis.
Its key clinical advantage over first-generation cephalosporins and amoxicillin is beta-lactamase stability — it resists enzymatic degradation by many resistant organisms, making cefuroxime axetil syrup the preferred step-up choice when first-line antibiotics have failed or resistant pathogens are suspected.
Cefuroxime Syrup Uses — Bacterial Infections in Children This Formulation Covers
Cefuroxime syrup uses for child span the most common infection types managed across pediatric primary care and ENT practice in India:
Ear Infections (Acute Otitis Media) — High middle ear fluid concentrations make cefuroxime axetil syrup effective against the dominant AOM pathogens — H. influenzae and S. pneumoniae — particularly in treatment-resistant cases.
Throat & Tonsil Infections — Clinical evidence shows cefuroxime achieves superior cure rates in streptococcal tonsillopharyngitis versus penicillin, attributed to its broader spectrum and beta-lactamase stability.
Chest & Lower Respiratory Infections — Covers bronchitis and community-acquired pneumonia pathogens in children requiring oral therapy or step-down from IV treatment.
Sinusitis — Acute bacterial sinusitis caused by the same ENT pathogens responds reliably to sinusitis antibiotic syrup for children formulations containing cefuroxime.
Urinary Tract Infections — High urinary concentrations and gram-negative coverage make this a proven urinary tract infection antibiotic syrup choice for pediatric UTI caused by E. coli.
Skin & Soft Tissue Infections — Impetigo and other pediatric skin infections involving S. aureus or S. pyogenes are appropriately managed with cefuroxime dry syrup pediatric formulations where oral treatment is indicated.
Third Party & Contract Manufacturing — Cefuroxime Axetil Dry Syrup
Delwis Healthcare serves as a third party pharmaceutical manufacturer and CDMO partner for pediatric brands, hospital supply companies, and exporters building their children's antibiotic range with cefuroxime axetil oral suspension IP.
Third Party Manufacturing — Your brand, our GMP production. Includes 30ml bottle, WFI, flavouring, label, and carton — zero manufacturing investment from your side.
Contract Manufacturing (CDMO) — From API qualification and formulation development through process validation, stability studies, and commercial batch supply — with complete CDSCO-compliant documentation.
Private Label Manufacturing — Custom brand name, bottle label, carton artwork, and flavor profile tailored to your target pediatric segment.
Bulk Supply — Commercial-scale batches for institutional procurement, government tender, and export markets with full batch COA and regulatory documentation.
Packaging & Reconstitution — 30ml Dry Syrup Bottle with WFI
Cefuroxime axetil dry syrup 125mg is supplied as dry powder in a 30ml amber glass bottle with a separate WFI ampoule:
- Dry powder format preserves API stability over the full 24-month pre-reconstitution shelf life
- WFI diluent ensures sterile, particle-free reconstitution
- Reconstituted suspension delivers 125mg cefuroxime per 5ml
- Post-reconstitution: use within 7 days, store below 25°C
Custom labeling and branded carton designs are fully supported for all third party manufacturing buyers.
Quality Control — Pediatric Dry Syrup Manufacturing Standards
Every batch of cefuroxime axetil oral suspension manufactured at Delwis Healthcare clears a validated multi-stage QC programme before release:
- HPLC Assay — Cefuroxime axetil API content verified against reference standard per batch
- Reconstitution Testing — Clarity, homogeneity, pH, and suspension uniformity post-reconstitution
- Dissolution & Particle Size — API particle size distribution and dissolution profile confirmed per IP/USP specification
- Content Uniformity — Dose consistency across sampled units within each batch
- Microbial Limit Testing — Microbiological safety compliance for oral pediatric formulations
- Stability Studies — Real-time and accelerated ICH-compliant data available for regulatory submissions
- Raw Material Testing — API and excipient verification including flavoring agents before production
Why Pharmaceutical Brands Choose Delwis Healthcare for Pediatric Dry Syrup Manufacturing
Pediatric medicine brands and hospital supply companies partner with Delwis Healthcare for cefuroxime axetil dry syrup contract manufacturing because:
- WHO-GMP & ISO 9001/14001 Certified — Compliant for CDSCO domestic registration and international export market submissions
- Dedicated Pediatric Dry Syrup Facility — Purpose-built production suites with humidity-controlled blending, filling, and sealing for oral suspension manufacturing
- WFI-Based Reconstitution — Sterile diluent standard maintained across all pediatric antibiotic dry syrups
- Palatability-Optimised Formulation — Child-acceptable taste and suspension texture for compliance in the 3-month to 12-year age group
- Flexible MOQ — Scalable from pilot validation batches to large commercial runs
- Full CDMO Support — Formulation development, stability data, and regulatory dossier documentation
- Export-Ready Documentation — COA, COPP, FSC, and stability packages available for African, Asian, and Middle Eastern market registrations
- Competitive Manufacturing Cost — Cost-efficient pediatric antibiotic production from Ahmedabad, Gujarat
Cefuroxime Axetil Syrup — Questions Prescribers & Pediatric Brands Ask Most
Q1: What is cefuroxime axetil syrup used for in children?
Cefuroxime axetil syrup uses cover bacterial ear infections (acute otitis media), tonsillitis, sinusitis, bronchitis, community-acquired pneumonia, urinary tract infections, and skin infections in children from 3 months to 12 years. It is particularly effective where beta-lactamase-producing organisms are involved and first-line antibiotics have shown inadequate response.
Q2: What is the cefuroxime dosage for children by weight?
Standard cefuroxime axetil dosage for children by weight is 15–30mg/kg/day in two divided doses. For a 10kg child at 15mg/kg, this equals approximately 6ml/day of 125mg/5ml suspension split into two 3ml doses. The treating pediatrician determines the appropriate dose based on indication, severity, and child's weight.
Q3: How do you reconstitute cefuroxime axetil dry syrup?
Add the provided WFI gradually to the dry powder, cap the bottle, and shake until a uniform suspension forms. Shake before every use. The reconstituted suspension is stable for 7 days below 25°C — discard any remainder after this period.
Q4: Should cefuroxime syrup be given before or after food?
Cefuroxime axetil is best taken with or just after food — food significantly increases oral bioavailability by improving prodrug absorption in the intestinal mucosa. Parents should be counselled accordingly to administer the dose with a meal for optimal efficacy.
Q5: Is cefuroxime axetil syrup safe for infants from 3 months?
Yes. Cefuroxime axetil dry syrup is approved from 3 months of age with weight-based dosing. It has a well-established pediatric safety profile. Use in very young infants should always be under direct medical supervision.
Q6: Cefuroxime vs amoxicillin clavulanate — which is better for children?
Both are effective second-line options for beta-lactamase-producing pediatric infections. Cefuroxime generally causes less diarrhea than amoxicillin-clavulanate — a clinically important tolerability advantage in young children where GI side effects reduce compliance. The treating pediatrician selects the appropriate agent based on infection type and local resistance patterns.
Q7: What are the side effects of cefuroxime suspension in children?
Cefuroxime suspension side effects are generally mild — most commonly loose stools or diarrhea, nausea, and abdominal discomfort. Hypersensitivity reactions are uncommon but possible in children with known cephalosporin or penicillin allergy. Diaper rash may occur in very young infants. Discontinue and seek medical advice if signs of allergic reaction develop.
Q8: Do you offer third party manufacturing for cefuroxime axetil dry syrup?
Yes. Delwis Healthcare offers complete third party and contract manufacturing of cefuroxime axetil 125mg/5ml oral suspension IP in 30ml bottles with WFI — under your brand name, with custom labeling, carton packaging, and full regulatory documentation for Indian and export markets. Contact info@delwishealthcare.com for enquiries.
